Prognostic Factors and Treatment Outcomes in 93 Patients with Uterine Sarcoma from 4 Centers in Turkey

Basit Öğe Kaydı
dc.contributor.authorDurnali, Ayse
dc.contributor.authorTokluoglu, Saadet
dc.contributor.authorOzdemir, Nuriye
dc.contributor.authorInanc, Mevlude
dc.contributor.authorAlkis, Necati
dc.contributor.authorZengin, Nurullah
dc.contributor.authorSonmez, Ozlem Uysal
dc.date.accessioned2024-04-24T17:28:15Z
dc.date.available2024-04-24T17:28:15Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractIntroduction: Uterine sarcomas are a group of heterogenous and rare malignancies of the female genital tract and there is a lack of consensus on prognostic factors and optimal treatment. Objective and Methodology: To perform a retrospective evaluation of clinicopathological characteristics, prognostic factors and treatment outcomes of 93 patients with uterine sarcomas who were diagnosed and treated at 4 different centers from November 2000 to October 2010. Results: Of the 93 patients, 58.0% had leiomyosarcomas, 26.9% malignant mixed Mullerian tumors, 9.7% endometrial stromal sarcomas, and 5.4% other histological types. According to the last International Federation of Gynecology and Obstetrics (FIGO) staging, 43.0% were stage I, 20.4% were stage II, 22.6% were stage III and 14.0 % were stage IV. Median relapse free survival (RFS) was 20 months (95% confidence interval (CI), 12.4-27.6 months), RFS after 1, 2, 5 years were 66.6%, 44.1%, 16.5% respectively. Median overall survival (OS) was 56 months (95% CI, 22.5-89.5 months), and OS after 1, 2, 5 years was 84.7%, 78%, 49.4% respectively. Multivariate analysis showed that age >= 60 years and high grade tumor were significantly associated with poor OS and RFS; patients administered adjuvant treatment with sequential chemotherapy and radiotherapy had longer RFS time. Among patients with leiomyosarcoma, in addition to age and grade, adjuvant treatment with sequential chemotherapy and radiotherapy after surgery had significant effects on OS. Conclusion: Uterine sarcomas have poor progrosis even at early stages. Prognostic factors affecting OS were found to be age and grade.en_US
dc.identifier.doi10.7314/APJCP.2012.13.5.1935
dc.identifier.endpage1941en_US
dc.identifier.issn1513-7368
dc.identifier.issue5en_US
dc.identifier.pmid22901150
dc.identifier.scopus2-s2.0-84872687747
dc.identifier.scopusqualityQ3
dc.identifier.startpage1935en_US
dc.identifier.urihttps://doi.org/10.7314/APJCP.2012.13.5.1935
dc.identifier.urihttps://hdl.handle.net/11468/20381
dc.identifier.volume13en_US
dc.identifier.wosWOS:000309470100042
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAsian Pacific Organization Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal of Cancer Prevention
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectUterine Sarcomaen_US
dc.subjectLeiomyosarcomaen_US
dc.subjectMalignant Mixed Mullerian Tumoren_US
dc.subjectPrognostic Factorsen_US
dc.subjectTurkeyen_US
dc.titlePrognostic Factors and Treatment Outcomes in 93 Patients with Uterine Sarcoma from 4 Centers in Turkeyen_US
dc.titlePrognostic Factors and Treatment Outcomes in 93 Patients with Uterine Sarcoma from 4 Centers in Turkey
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu